Dexcom Files Routine 8-K, Confirms Nasdaq Listing

TL;DR

**Dexcom filed a standard 8-K, no new news, just regulatory compliance.**

AI Summary

This 8-K filing from Dexcom, Inc. on January 8, 2024, is a routine administrative update, primarily confirming its status as a publicly traded company on the Nasdaq Global Select Market under the ticker DXCM. It doesn't contain new financial results or significant operational changes, but rather formalizes its current reporting obligations. For investors, this filing simply reaffirms Dexcom's ongoing compliance with SEC regulations, indicating business as usual without any immediate impact on stock valuation.

Why It Matters

This filing is a standard procedural update, confirming Dexcom's compliance with SEC reporting requirements and its listing on the Nasdaq Global Select Market. It signals stability rather than any new developments.

Risk Assessment

Risk Level: low — This 8-K is a purely administrative filing and does not introduce any new financial or operational risks.

Analyst Insight

This filing is purely administrative and provides no new information that would warrant an immediate investment action. Investors should continue to monitor for financial results or strategic announcements.

Key Numbers

• $0.001 — Par Value Per Share (the stated par value of Dexcom's Common Stock)

Key Players & Entities

• DEXCOM, INC. (company) — the registrant filing the 8-K
• Nasdaq Global Select Market (company) — the exchange where Dexcom's common stock is registered
• DXCM (company) — the trading symbol for Dexcom's common stock
• January 8, 2024 (date) — the date of the earliest event reported and filing date
• 000-51222 (dollar_amount) — Commission File Number

FAQ

From the Filing

0001093557-24-000003.txt : 20240108 0001093557-24-000003.hdr.sgml : 20240108 20240108080259 ACCESSION NUMBER: 0001093557-24-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 24518414 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20240108.htm 8-K dxcm-20240108 false 0001093557 0001093557 2024-01-08 2024-01-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. In connection with remarks to be made at the J.P. Morgan 42nd Annual Healthcare Conference on Monday, January 8, 2024, beginning at 12:45 p.m. (Eastern Time), DexCom, Inc. (“Dexcom”) Chairman, President and Chief Executive Officer, Kevin Sayer, will report that preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 is expected to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022. For fiscal year 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion, an increase of 24% over 2022. Finally, Mr. Sayer will provide Dexcom’s initial financial outlook for fiscal year 2024, including an anticipated range for total revenue of approximately $4.15 billion to $4.35 billion. The fourth quarter and fiscal year 2023 preli